Locust Walk Acquisition Corp - Ordinary Shares - Class A

NASDAQ:LWAC  
9.88
+0.02 (+0.15%)
Mergers / Acquisitions

Effector Therapeutics And Locust Walk Acquisition Corp. Announce Merger Agreement To Create Publicly Listed, Next-Generation Oncology Company Developing New Class Of Cancer Therapies

Published: 05/27/2021 12:11 GMT
Locust Walk Acquisition Corp - Ordinary Shares - Class A (LWAC) - Effector Therapeutics and Locust Walk Acquisition Corp.
Announce Merger Agreement to Create Publicly Listed, Next-generation Oncology Company Developing New Class of Cancer Therapies.
Effector Therapeutics - Gross Proceeds Expected to Include $60 Million From a Committed Pipe and Up to $175 Million Held in Trust.
Effector Therapeutics - Merger Expected to Be Completed in Q3 of 2021; Combined Company Expected to Be Listed on Nasdaq Under the Ticker “eftr”.
Effector Therapeutics - Upon Closing, Effector Would Be Expected to Have Cash Resources of About $210 Million & Total Enterprise Valuation of $419 Million.